Applied DNA Sciences to Showcase Its Advanced Supply Chain Security Technologies at INTERPHEX 2014

Applied DNA Sciences will show technologies based on its SigNature® DNA family of products, offering packagers and brands a true forensic check for authenticity and traceability. A suite of optical and digital technologies and in-field detection tools can be integrated with the solution to tailor it to a customer’s security needs.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Stony Brook, New York (PRWEB) March 17, 2014

Applied DNA Sciences (OTCQB: APDN), (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, along with business partner DISC, will be showcasing its solutions for pharmaceutical packaging at INTERPHEX, a leading pharmaceutical and biopharmaceutical tradeshow. The show will run from March 18-20.

APDN technologies are based on its SigNature® DNA family of products, offering packagers and brands a true forensic check for authenticity and traceability. A suite of optical and digital technologies and in-field detection tools can be integrated with the solution to tailor it to a customer’s security needs.

Business partner DISC, a leader in creative packaging and printing solutions, can incorporate these technologies according to the specific needs of its customers.

INTERPHEX attendees are invited to stop by booth 3719 to speak with a knowledgeable APDN representative about their company's diversion, counterfeiting, or other supply chain assurance needs.

APDN technologies on display will include:

– Signature DNA: for package and label printing, embedded with a unique mark based on botanical DNA. This uncopyable mark forensically verifies the origin of a product, using an analysis that will stand up to any audit and in court.

Nearly 1 billion packages have been marked to date with SigNature DNA.

– SigNature Beacon detection: preview of a new technology using a proprietary new "lock and key" method to quickly verify the presence of the DNA mark.

– Bar code-based track and trace: integrated with SigNature DNA and, potentially, Beacon technologies, this capability adds insight from serialization, chain-of-custody or other logistical tracking data. A mobile solution offered together with partner InData Systems can scan an entirely covert barcode.

APDN pharma packaging technologies may be layered to produce a truly comprehensive supply chain security platform.

John Rebecchi, Senior Vice President, Marketing and New Business Development of DISC, commented, "At DISC we help build and protect your brand, and grow your business. Applied DNA Sciences adds advanced technology to protect against counterfeiting and diversion. It is the kind of creative solution that we believe the industry is searching for."

Dr. James A. Hayward, CEO and President of Applied DNA Sciences, stated:

"Pharmaceutical and biopharmaceutical supply chain assurance is a strategic priority for Applied DNA Sciences. We are excited to present our range of anti-counterfeiting, anti-diversion and comprehensive supply chain security technologies to attendees at INTERPHEX. "

For more information about APDN's complete set of offerings for the biopharmaceutical and pharmaceutical industries, please visit http://www.adnas.com/documents-and-packaging.

For more detail on INTERPHEX, visit:
http://bit.ly/1g0PYsy

About Applied DNA Sciences

APDN is a provider of botanical-DNA based security and authentication solutions that can help protect products, brands and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA and DNANet, our principal anti-counterfeiting and product authentication solutions that essentially cannot be copied, provide a forensic chain of evidence and can be used to prosecute perpetrators.

The statements made by APDN may be forward-looking in nature. Forward-looking statements describe APDNs future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDNs SEC reports and filings, including our Annual Report on Form 10-K, filed on December 20, 2013 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.


Contact